Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Navdeep Pal

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2024
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancerMariano Provencio-Pulla, Diego Pérez-Parente, Sara Olson, et al.
Obstetrics and Gynecology|December 8, 2017
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine DeviceNavdeep Pal, Russell R Broaddus, Diana L Urbauer, et al.
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
American Journal of Obstetrics and Gynecology|August 18, 2020
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancerShannon N Westin, Bryan Fellman, Charlotte C Sun, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2024
Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancerMariano Provencio-Pulla, Diego Pérez-Parente, Sara Olson, et al.
Obstetrics and Gynecology|December 8, 2017
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine DeviceNavdeep Pal, Russell R Broaddus, Diana L Urbauer, et al.
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
American Journal of Obstetrics and Gynecology|August 18, 2020
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancerShannon N Westin, Bryan Fellman, Charlotte C Sun, et al.
Pageof 2